Abstract | PURPOSE: METHODS: RESULTS: At final visit, the mean number of ranibizumab injections was 4.5 ± 1.29. From baseline to final visit, 21 of 24 eyes (87.5%) lost fewer than 3 lines of visual acuity. Mean best-corrected visual acuity did not change significantly from baseline to final visit (0.37 ± 0.2 logarithm of the minimum angle of resolution vs. 0.30 ± 0.25 logarithm of the minimum angle of resolution, respectively; P = 0.115). Mean central macular thickness significantly decreased from baseline to final visit (327 ± 83 μm vs. 260 ± 57 μm, respectively; P = 0.001). CONCLUSION:
|
Authors | Gérard Mimoun, Violaine Caillaux, Giuseppe Querques, Pierre-Raphaël Rothschild, Nathalie Puche, Eric H Souied |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 33
Issue 3
Pg. 513-21
(Mar 2013)
ISSN: 1539-2864 [Electronic] United States |
PMID | 23400081
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Coloring Agents
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Indocyanine Green
- Ranibizumab
|
Topics |
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal, Humanized
(administration & dosage, therapeutic use)
- Choroidal Neovascularization
(diagnosis, drug therapy, physiopathology)
- Coloring Agents
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Humans
- Indocyanine Green
- Intravitreal Injections
- Male
- Ranibizumab
- Retrospective Studies
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(physiology)
- Vitelliform Macular Dystrophy
(diagnosis, drug therapy, physiopathology)
|